[Skip to Navigation]
October 1989

Recommendations of the Immunization Practices Advisory Committee (ACIP) Mumps Prevention

Am J Dis Child. 1989;143(10):1141-1142. doi:10.1001/archpedi.1989.02150220031015

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


THIS REVISED Immunization Practices Advisory Committee (AC IP) recommendation on mumps vaccine updates the 1982 recommendation.

MUMPS VIRUS VACCINE  Mumps virus vaccine is prepared in chick-embryo cell culture. The vaccine produces a subclinical, noncommunicable infection with very few side effects. Mumps vaccine is available both in monovalent (mumps only) form and in combinations: mumps-rubella and measles-mumps-rubella (MMR) vaccines.The vaccine is approximately 95% efficacious in preventing mumps disease; greater than 97% of persons known to be susceptible to mumps develop measurable antibody following vaccination. Vaccine-induced antibody is protective and long-lasting, although of considerably lower titer than antibody resulting from natural infection. The duration of vaccine-induced immunity is unknown, but serologic and epidemiologic data collected during 20 years of live vaccine use indicate both the persistence of antibody and continuing protection against infection. Estimates of clinical vaccine efficacy ranging from 75% to 95% have been calculated from data collected in outbreak

First Page Preview View Large
First page PDF preview
First page PDF preview
Add or change institution